Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616027 · ClinicalTrials.gov registry record · Phase 1
Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment
A Phase 1 study of Healthy and Diabetes Mellitus, Type 2, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT04616027: Completed Phase 1 study of Healthy and Diabetes Mellitus, Type 2, sponsored by Pfizer.
NCT04616027 is a Phase 1 study of Healthy and Diabetes Mellitus, Type 2 that has completed, run by Pfizer. The registered enrollment target is 42 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04616027, a Phase 1 study of Healthy and Diabetes Mellitus, Type 2, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
Primary Outcome
Cmax was the maximum observed plasma concentration and was directly observed from data.
Conditions Studied
Interventions
- DRUG PF-06882961 20 mg
Study Locations (3)
Florida
- University of Miami Hospital - Miami
- Orlando Clinical Research Center - Orlando
Minnesota
- Prism Research LLC dba Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 1 |
What the finished NCT04616027 record still lists
NCT04616027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PF-06882961 20 mg is the first listed.
NCT04616027 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04616027 about?
NCT04616027 is a clinical study titled "Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment". This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
What is the current status of trial NCT04616027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-01-13. Estimated completion is 2022-02-18.
What conditions does trial NCT04616027 study?
This clinical trial studies the following conditions: Healthy, Diabetes Mellitus, Type 2, Renal Impairment.
What interventions are being tested in trial NCT04616027?
The interventions under investigation include: PF-06882961 20 mg (DRUG).
Who is sponsoring clinical trial NCT04616027?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04616027 being conducted?
This trial has 3 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04616027's enrollment target sits among peer trials
42 525th of 1090 higher than 556 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI